Does the media favor MIRM or KLRA?

In the previous week, Mirum Pharmaceuticals had 17 more articles in the media than Kailera Therapeutics. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 7 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Mirum Pharmaceuticals' score of 0.72 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KLRA or COGT?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A

Is KLRA or COGT more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Cogent Biosciences N/A -84.47% -47.72%

Does the media favor KLRA or TVTX?

In the previous week, Kailera Therapeutics had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 7 mentions for Kailera Therapeutics and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.91 beat Kailera Therapeutics' score of 0.85 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KLRA or CRSP?

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Kailera Therapeutics. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 7 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat CRISPR Therapeutics' score of 0.35 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KLRA or PTCT more profitable?

Kailera Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A PTC Therapeutics -3.80% N/A -1.32%

Does the media prefer KLRA or PTCT?

In the previous week, PTC Therapeutics had 12 more articles in the media than Kailera Therapeutics. MarketBeat recorded 19 mentions for PTC Therapeutics and 7 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat PTC Therapeutics' score of 0.43 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Kailera Therapeutics (KLRA) Competitors

$10.77 -0.56 (-4.94%)

As of 10/13/2026 04:00 PM Eastern

Compare

KLRA vs. MIRM, COGT, TVTX, CRSP, and PTCT

Should you buy Kailera Therapeutics stock or one of its competitors? Kailera Therapeutics's main competitors and comparable companies include Mirum Pharmaceuticals (MIRM), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), CRISPR Therapeutics (CRSP), and PTC Therapeutics (PTCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kailera Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

In the previous week, Mirum Pharmaceuticals had 17 more articles in the media than Kailera Therapeutics. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 7 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Mirum Pharmaceuticals' score of 0.72 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Kailera Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	9.92	-$23.36M	-$14.55	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Kailera Therapeutics' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Kailera Therapeutics	N/A	N/A	N/A

Mirum Pharmaceuticals currently has a consensus price target of $146.63, indicating a potential upside of 84.16%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 296.94%. Given Kailera Therapeutics' higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Mirum Pharmaceuticals beats Kailera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kailera Therapeutics compare to Cogent Biosciences?

Kailera Therapeutics (NASDAQ:KLRA) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Kailera Therapeutics currently has a consensus target price of $42.75, indicating a potential upside of 296.94%. Cogent Biosciences has a consensus target price of $51.56, indicating a potential upside of 83.54%. Given Kailera Therapeutics' higher possible upside, analysts plainly believe Kailera Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kailera Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Cogent Biosciences	N/A	-84.47%	-47.72%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

In the previous week, Kailera Therapeutics had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Kailera Therapeutics and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Kailera Therapeutics' score of 0.85 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Kailera Therapeutics	Positive
Cogent Biosciences	Very Positive

Summary

Kailera Therapeutics beats Cogent Biosciences on 5 of the 8 factors compared between the two stocks.

How does Kailera Therapeutics compare to Travere Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Kailera Therapeutics presently has a consensus price target of $42.75, indicating a potential upside of 296.94%. Travere Therapeutics has a consensus price target of $69.50, indicating a potential upside of 34.17%. Given Kailera Therapeutics' higher probable upside, research analysts plainly believe Kailera Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Kailera Therapeutics had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 7 mentions for Kailera Therapeutics and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.91 beat Kailera Therapeutics' score of 0.85 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has higher revenue and earnings than Kailera Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Travere Therapeutics	$490.73M	9.95	-$25.55M	-$0.46	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Kailera Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Summary

Kailera Therapeutics beats Travere Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kailera Therapeutics compare to CRISPR Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Kailera Therapeutics currently has a consensus target price of $42.75, indicating a potential upside of 296.94%. CRISPR Therapeutics has a consensus target price of $67.50, indicating a potential upside of 34.73%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.68

Kailera Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. Kailera Therapeutics' return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kailera Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
CRISPR Therapeutics	$3.51M	1,380.11	-$581.60M	-$4.76	N/A

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Kailera Therapeutics. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 7 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat CRISPR Therapeutics' score of 0.35 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kailera Therapeutics and CRISPR Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Kailera Therapeutics compare to PTC Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Kailera Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
PTC Therapeutics	-3.80%	N/A	-1.32%

Kailera Therapeutics presently has a consensus price target of $42.75, suggesting a potential upside of 296.94%. PTC Therapeutics has a consensus price target of $98.25, suggesting a potential upside of 63.97%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kailera Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, PTC Therapeutics had 12 more articles in the media than Kailera Therapeutics. MarketBeat recorded 19 mentions for PTC Therapeutics and 7 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat PTC Therapeutics' score of 0.43 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has higher revenue and earnings than Kailera Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
PTC Therapeutics	$1.73B	2.89	$682.64M	-$0.58	N/A

Summary

Kailera Therapeutics and PTC Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRA vs. The Competition

Export

Metric	Kailera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.47B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	9.98	195.99	19.34
Price / Sales	N/A	1,149.11	562.25	81.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	N/A	16.95	10.71	6.03
Net Income	-$148.96M	-$22.69M	$3.50B	$380.34M
7 Day Performance	2.28%	-4.44%	-2.90%	-2.32%
1 Month Performance	-21.67%	-12.51%	-7.37%	-5.29%
1 Year Performance	N/A	7.77%	3.05%	-2.94%

Kailera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRA Kailera Therapeutics	2.3703 of 5 stars	$10.77 -4.9%	$42.75 +296.9%	N/A	$1.47B	N/A	N/A	145	Lockup Expiration
MIRM Mirum Pharmaceuticals	3.1331 of 5 stars	$82.93 -1.2%	$142.56 +71.9%	+10.3%	$5.38B	$521.31M	N/A	433	Trending News Analyst Forecast Analyst Revision
COGT Cogent Biosciences	2.8363 of 5 stars	$31.02 -1.8%	$51.56 +66.2%	+73.4%	$5.38B	N/A	N/A	258	Positive News
TVTX Travere Therapeutics	3.1579 of 5 stars	$56.93 +0.1%	$69.50 +22.1%	+97.7%	$5.37B	$490.73M	N/A	497
CRSP CRISPR Therapeutics	3.4331 of 5 stars	$55.43 0.0%	$67.94 +22.6%	-26.6%	$5.36B	$3.51M	N/A	393

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kailera Therapeutics (KLRA) Competitors

KLRA vs. MIRM, COGT, TVTX, CRSP, and PTCT

How does Kailera Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Kailera Therapeutics compare to Cogent Biosciences?

Summary

How does Kailera Therapeutics compare to Travere Therapeutics?

Summary

How does Kailera Therapeutics compare to CRISPR Therapeutics?

Summary

How does Kailera Therapeutics compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kailera Therapeutics (KLRA) Competitors

KLRA vs. MIRM, COGT, TVTX, CRSP, and PTCT

How does Kailera Therapeutics compare to Mirum Pharmaceuticals?

Does the media favor MIRM or KLRA?

Which has preferable earnings & valuation, MIRM or KLRA?

Is MIRM or KLRA more profitable?

Do analysts rate MIRM or KLRA?

Summary

How does Kailera Therapeutics compare to Cogent Biosciences?

Do analysts rate KLRA or COGT?

Is KLRA or COGT more profitable?

Which has higher earnings and valuation, KLRA or COGT?

Does the media favor KLRA or COGT?

Summary

How does Kailera Therapeutics compare to Travere Therapeutics?

Do analysts prefer KLRA or TVTX?

Does the media favor KLRA or TVTX?

Which has higher valuation & earnings, KLRA or TVTX?

Is KLRA or TVTX more profitable?

Summary

How does Kailera Therapeutics compare to CRISPR Therapeutics?

Do analysts prefer KLRA or CRSP?

Is KLRA or CRSP more profitable?

Do insiders and institutionals believe in KLRA or CRSP?

Which has preferable earnings and valuation, KLRA or CRSP?

Does the media prefer KLRA or CRSP?

Summary

How does Kailera Therapeutics compare to PTC Therapeutics?

Is KLRA or PTCT more profitable?

Do analysts recommend KLRA or PTCT?

Does the media prefer KLRA or PTCT?

Which has better valuation & earnings, KLRA or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools